Další formáty:
BibTeX
LaTeX
RIS
@article{949470,
author = {Fiegl, Michael and Falkner, Florian and Steurer, Michael and Zojer, Niklas and Hopfinger, Georg and Haslbauer, Ferdinand and Winder, Guntram and Voskova, Daniela and Andel, Johannes and Lang, Alois and Brychtová, Yvona and Mayer, Jiří and Greil, Richard and Gastl, Günther},
article_number = {9},
doi = {http://dx.doi.org/10.1007/s00277-011-1192-5},
keywords = {Alemtuzumab; Retreatment; Chronic lymphocytic leukemia; CLL; Retrospective survey},
language = {eng},
issn = {0939-5555},
journal = {Annals of Hematology},
title = {Successful alemtuzumab retreatment in progressive B-cell chronic lymphocytic leukemia: a multicenter survey in 30 patients},
url = {http://www.springerlink.com/content/dg8n22557w62672k/fulltext.pdf},
volume = {90},
year = {2011}
}
TY - JOUR
ID - 949470
AU - Fiegl, Michael - Falkner, Florian - Steurer, Michael - Zojer, Niklas - Hopfinger, Georg - Haslbauer, Ferdinand - Winder, Guntram - Voskova, Daniela - Andel, Johannes - Lang, Alois - Brychtová, Yvona - Mayer, Jiří - Greil, Richard - Gastl, Günther
PY - 2011
TI - Successful alemtuzumab retreatment in progressive B-cell chronic lymphocytic leukemia: a multicenter survey in 30 patients
JF - Annals of Hematology
VL - 90
IS - 9
SP - 1083-1091
EP - 1083-1091
SN - 09395555
KW - Alemtuzumab
KW - Retreatment
KW - Chronic lymphocytic leukemia
KW - CLL
KW - Retrospective survey
UR - http://www.springerlink.com/content/dg8n22557w62672k/fulltext.pdf
N2 - Although retreatment with alemtuzumab in relapsing B-cell chronic lymphocytic leukemia (CLL) may be beneficial, there has thus far been no thorough analysis available on this topic. Data were collected from 30 chemotherapy-pretreated patients with progressive CLL who had received alemtuzumab twice in consecutive, distinct therapy lines. The median dose of alemtuzumab retreatment was 402 mg (range, 43–1,090 mg). Retreatment with alemtuzumab induced an overall response rate of 47%. From the start of alemtuzumab retreatment, median progression-free survival (PFS) and overall survival (OS) were 6.3 and 20.0 months, respectively. Response rates, PFS and OS upon alemtuzumab retreatment were correlated with response to initial alemtuzumab treatment, the time interval between the initial course of alemtuzumab and start of retreatment, and the hemoglobin concentration prior to retreatment. Reported toxicities from 24 cases included infections (50%), febrile reactions upon alemtuzumab administration (38%), exanthema (21%), and grade 4 neutropenia (13%) and thrombocytopenia (17%). We conclude that alemtuzumab retreatment represents an effective and tolerable therapeutic option for selected patients with CLL.
ER -
FIEGL, Michael, Florian FALKNER, Michael STEURER, Niklas ZOJER, Georg HOPFINGER, Ferdinand HASLBAUER, Guntram WINDER, Daniela VOSKOVA, Johannes ANDEL, Alois LANG, Yvona BRYCHTOVÁ, Jiří MAYER, Richard GREIL a Günther GASTL. Successful alemtuzumab retreatment in progressive B-cell chronic lymphocytic leukemia: a multicenter survey in 30 patients. \textit{Annals of Hematology}. 2011, roč.~90, č.~9, s.~1083-1091. ISSN~0939-5555. Dostupné z: https://dx.doi.org/10.1007/s00277-011-1192-5.
|
